CDK4/6 Inhibitors vs Chemotherapy for Patients with Metastatic Breast Cancer

Conference Correspondent  - Breast Cancer, Video, SABCS
Hope S. Rugo, MD
Despite international guidelines and data that show CDK4/6 inhibitors plus aromatase inhibitors can improve overall response rates, overall survival, and progression-free survival in patients with metastatic breast cancer, there is a lasting belief among patients that chemotherapy is the preferable course of treatment. Dr. Hope Rugo attempts to dispel this misconception, citing that endocrine therapy and CDK4/6 inhibitors are well tolerated and don’t have the intensive side effects associated with chemotherapy.
Related Items
Management of Adverse Events Associated with PARP Inhibitors as First-Line Maintenance Therapy in Ovarian Cancer
Ali McBride, PharmD, MS, BCPS, Paula Anastasia, RN, MN, AOCN
Videos published on October 11, 2020 in Interview with the Innovators, Video
Combination Therapy as Maintenance in Ovarian Cancer
Amina Ahmed, MD, Ali McBride, PharmD, MS, BCPS, Paula Anastasia, RN, MN, AOCN
Videos published on October 6, 2020 in Interview with the Innovators, Video
Clinical Data on First-Line Maintenance Therapy in Ovarian Cancer
Amina Ahmed, MD, Ali McBride, PharmD, MS, BCPS, Paula Anastasia, RN, MN, AOCN
Videos published on September 15, 2020 in Interview with the Innovators, Video
Pembrolizumab Added to First-Line Chemotherapy Improves Progression-Free Survival in Metastatic TNBC
William King
TOP - September 2020 Vol 13, No 5 published on September 14, 2020 in Breast Cancer
Choosing Among PARP Inhibitors as Maintenance Therapy in Ovarian Cancer
Amina Ahmed, MD, Ali McBride, PharmD, MS, BCPS, Paula Anastasia, RN, MN, AOCN
Videos published on September 8, 2020 in Interview with the Innovators, Video
Choosing Maintenance Therapy in Ovarian Cancer
Amina Ahmed, MD, Ali McBride, PharmD, MS, BCPS, Paula Anastasia, RN, MN, AOCN
Videos published on August 18, 2020 in Interview with the Innovators, Video
A Review of Clinical Trials Suggesting the Use of PARP Inhibitors as First-Line Maintenance Therapy in Ovarian Cancer
Amina Ahmed, MD, Ali McBride, PharmD, MS, BCPS, Paula Anastasia, RN, MN, AOCN
Videos published on August 11, 2020 in Interview with the Innovators, Video
Changes in HRD “Fingerprints” in Patients with Ovarian Cancer and Their Impact on Clinical Outcomes
Amina Ahmed, MD, Paula Anastasia, RN, MN, AOCN
Videos published on July 28, 2020 in Interview with the Innovators, Video
Capecitabine Improves Outcomes in TNBC When Added to Other Systemic Therapy
TOP - July 2020, Vol 13, No 4 published on July 15, 2020 in Breast Cancer
The Impact of Germline or Somatic HRD Testing on Treatment Decisions in Ovarian Cancer
Ali McBride, PharmD, MS, BCPS, Paula Anastasia, RN, MN, AOCN
Videos published on July 14, 2020 in Interview with the Innovators, Video
Last modified: April 27, 2020